Jane Street’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-9,115
Closed -$78.4K 10418
2024
Q1
$78.4K Buy
+9,115
New +$43.5K ﹤0.01% 8619
2023
Q2
Sell
-849
Closed -$32.1K 9799
2023
Q1
$32.1K Buy
+849
New +$27.8K ﹤0.01% 8559
2022
Q3
Sell
-503
Closed -$20K 10688
2022
Q2
$20K Sell
503
-17
-3% -$658 ﹤0.01% 9166
2022
Q1
$27K Buy
+520
New +$26.1K ﹤0.01% 9866
2021
Q1
Sell
-552
Closed -$129K 9706
2020
Q4
$129K Sell
552
-1,385
-72% -$193K ﹤0.01% 7126
2020
Q3
$200K Buy
+1,937
New +$104K ﹤0.01% 6435
2019
Q2
Sell
-84
Closed -$23K 5905
2019
Q1
$23K Buy
+84
New +$18.2K ﹤0.01% 4895

Other funds holding TCON

Jane Street's TCON Position: Q2 2024 in Review

Jane Street sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 9,115 shares — an estimated $78.4K sold.

Jane Street first reported a position in TCON in Q1 2019 and held it in 7 quarters. The position peaked at $200K in Q3 2020. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

  • Jane Street reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Jane Street sold 9,115 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $78.4K.
  • Jane Street first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
  • Jane Street's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $200K in Q3 2020.
  • 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Jane Street's 13F filing for Q2 2024, filed 15 Aug 2024.